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A B S T R A C T
Purpose: Little is known about the pharmacological effects of the phenolic compounds of Pennyroyal (Mentha
pulegium). This Mediterranean aromatic plant, used as a gastronomic spice and as food preservative by the food
industry has been studied mainly due to its essential oil antibacterial properties, composed primarily by
monoterpenes. With this work, we aimed to evaluate the effects of a phenolic extract of pennyroyal in the
impairment of inflammatory processes in Inflammatory Bowel Diseases (IBD) and in the potential inhibition of
progression to colorectal cancer (CRC).
Methods: To that purpose, we evaluated the effect of pennyroyal extract administration in a model of TNBS-
induced colitis in mice and further determined its effect on human colon carcinoma cell proliferation and in-
vasion.
Results: The phenolic extract of pennyroyal exhibited antioxidant properties in in vitro assays and administration
of the extract in a rat model of carrageenan-induced paw oedema led to significant anti-inflammatory effects.
Further results evidenced a beneficial effect of the phenolic extract in the attenuation of experimental colitis and
a potential antiproliferative effect on cultured colon cancer cells, effects not previously described, to our
knowledge. A reduction in several markers of colon inflammation was observed following administration of the
extract to colitis-induced mice, including functional and histological indicators. A successful inhibition of cancer
cell invasion and proliferation was also observed in in vitro studies with HT-29 cells. Furthermore, the extract
also led to a reduced expression of iNOS/COX-2 in the colon of colitis-induced mice, both being crucial med-
iators of intestinal inflammation.
Conclusions: Taking into consideration the central role of inflammation in the pathophysiology of CRC and the
recognised connection between inflammatory events and cancer, these results enlighten the relevance of the
phenolic constituents of pennyroyal as important pharmacological sources in the investigation of new treatment
options for patients with inflammatory bowel diseases.
1. Introduction
Inflammatory Bowel Diseases (IBD) is a term given to generally
characterize two types of intestinal diseases: Crohn’s Disease and
ulcerative colitis. Despite decades of extensive research on these dis-
eases, a specific aetiological cause is yet to be established, although the
aetiology of both diseases appear to be related to a dysregulated mu-
cosal immune response to environmental factors in genetically
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susceptible hosts [1,2].
Colorectal cancer (CRC) is one of the most common cancers
worldwide, with over 1.8 million new colorectal cancer cases and
881000 deaths estimated to have occurred in 2018, accounting for
about 1 in 10 cancer cases and deaths. Overall, colorectal cancer ranks
third in terms of incidence but second in terms of mortality [3]. Ad-
ditionally, CRC is the third most incident cancer in the male population
(10.9%) and the second most common in the female population (9.5%)
[3]. Interestingly, only ˜5–6% of CRC cases are related to germline
mutations [4], whereas ˜70% of CRC tumours are sporadic [5].
Taking this information into consideration, an opportunity might
exist to increase CRC prevention by decreasing its risk factors. In fact,
since the tumour initiation and progression processes are multifactorial,
they are also influenced by several external factors, especially regarding
the environment and diet, with the latter being able to either ameliorate
or even increase CRC risk [6]. In patients with IBD, chronic in-
flammation is known to be a major risk factor for the development of
gastrointestinal malignancies [7] with inflammatory signalling path-
ways associated with increased intestinal production of reactive oxygen
species being considered to be the main driving factor bridging IBD into
CRC [8,9]. The chronic inflammation found in IBD often leads to ab-
normal cell growth (dysplasia). Although these cells cannot be called
malignant, the probability of gaining anaplastic characteristics and
developing into cancer cells is higher [5,9].
Taking into account the beneficial role of phenolic acids in in-
flammatory processes and in cell proliferation, an opportunity exists for
an adjuvant therapy that not only reduces the intestinal inflammation
of IBD patients but may also have a potential preventive effect in the
evolution of highly proliferative, inflammatory and dysplastic cells into
carcinoma cells [10–12].
Pennyroyal [Mentha pulegium L. (Lamiaceae)] is a Mediterranean
aromatic plant, commonly used in gastronomy as a spice that recently
sparkled the interest of the food industry [13]. There is a growing in-
terest in replacing synthetic chemicals by natural products with
bioactive properties from plant origin. In that context, the application
of essential oils is becoming increasingly important as natural additives
for shelf-life prolongation of food products, substituting the use of
synthetic preservatives [14]. In fact, studies have shown that M. pule-
gium essential oil exhibited antibacterial activity against several bac-
terial strains [13,15]. Essential oils are a mix of volatile compounds,
and are regarded as a prime source of bioactive compounds, mainly
with antioxidative and antimicrobial properties [14], with the main
compounds studied with relation to those effects being of terpenoid
structures (e.g. pulegone, pinene, limonene) and have been the main
focus of research regarding this plant [13,15,16]. The toxicological
profile of pennyroyal preparations has also been subjected to extensive
research, and several constituents have been identified as hepatotoxic
and abortifacient. However, those effects are characteristic of terpenoid
compounds, specific constituents of the essential oil and therefore not
present in phenolic extracts [17].
In contrast, little is known about the pharmacological effects of the
phenolic compounds of M. pulegium. Chemically, the phenolic content
of M. pulegium is comparable to plants known to exhibit pharmacolo-
gical properties in experimental models of inflammation which in-
creases the interest regarding its potential to exert anti-inflammatory
actions [18–23].
In this study we evaluated the beneficial effect of a phenolic extract
of M. pulegium (pennyroyal) as a potential pharmacological tool in the
management of inflammatory processes associated to IBD and aiming to
assess the potential inhibition of cell progression to colorectal cancer
and its relation with the anti-inflammatory effect. Therefore, we as-
sessed the effect of M. pulegium extract in an experimental TNBS-in-
duced colitis model with further evaluation of a potential inhibitory
effect on proliferation and invasion properties of human colon carci-
noma cell.
2. Materials and methods
2.1. Reagents and chemicals
Ketamine (Imalgene® 1000) and xilazine (Rompun® 2%) were ac-
quired from Bio2 Produtos Veterinários (Lisboa, Portugal). Unless
otherwise stated, all remaining substances were acquired from Sigma-
Aldrich, Portugal.
2.2. Plant material and extract preparation
Fresh samples of Mentha pulegium L. were obtained from a local
cultivar (Lisboa, Portugal). Plants (leaves and stems) were washed
under running tap water and chopped into thin slices. Chopped plant
material (20 g) was than extracted with 100mL of ethanol (70%, v/v),
for 24 h, in the dark, at room temperature and under stirring. The re-
sulting extracts were filtered (Whatman, nº1) and ethanol was elimi-
nated in rotary evaporator at 40 °C (Heidolph LABOROTA 4001). Then,
extracts were centrifuged (6000g, 15min, 4 °C) (Sigma 4K-15C) and the
supernatants were divided into 1mL aliquots and stored at−50 °C until
future analyses.
2.3. Total phenolic and total flavonoid content
Total phenolic compounds were determined according to Kosar
et al. [24] and total flavonoid content was determined according to
Barros et al. [25]. Results of total phenolic content were expressed as
mg gallic acid equivalents (GAE) per mL extract and per g of dry plant
and results of total flavonoid content were expressed in μmol equiva-
lents of catechin (CE) per mL of extract and per g of dry plant.
2.4. High-performance liquid chromatography (HPLC)
The phenolic components of the aqueous extract were isolated using
solid phase extraction C18 columns. Briefly, 2mL of the aqueous extract
was added to the column and the adsorbed phenolic components were
eluted with aqueous formic acid (0.1% v/v) and acetonitrile. The
chromatographic separation was performed in a HPLC system
(SpectraSystem, Thermo), equipped with a diode array detector (DAD),
and a Thermo C-18 column. The eluents used were 0.1% formic acid
(solvent A) and a mixture of 90% acetonitrile + 9.9% water + 0.1%
formic acid (solvent B), and the flow rate was 0.8mL/min.
Identification of the main functional groups present in the extract was
performed by comparison of their UV spectra with those of re-
presentative standards analysed in the same conditions.
2.5. Antioxidant capacity
2.5.1. Cupric reducing antioxidant capacity (CUPRAC) assay
CUPRAC assay was performed according to the normal sample
measurement procedure as previously described [26]. Results were
expressed as μmol ascorbic acid equivalents (AAE) per mL of extract.
2.5.2. Ferric reducing antioxidant power (FRAP) assay
The FRAP assay was carried according to the procedure as pre-
viously described [27]. A calibration curve of ferrous sulphate
(0–1.25mM) was used and results were expressed as μmol Fe2+ per mL
of extract.
2.5.3. DPPH radical-scavenging assay
The DPPH assay was carried according to the procedure previously
described [28]. Results were expressed as mg ascorbic acid equivalents
(AAE) per mL of extract.
2.5.4. Superoxide anion radical-scavenging assay
The superoxide anion radical-scavenging assay was performed
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according to the procedure previously described [29]. Results were
expressed as μmol equivalents of gallic acid per mL of extract.
2.6. Carrageenan-induced paw oedema in rat
2.6.1. Animals
The paw oedema study was carried out using 48 male Wistar rats
(150–200 g) (Harlan - Spain). All rats had free access to water and food
until 12 h of the study.
2.6.2. Oedema induction and evaluation
Paw oedema was induced by intradermal (sub-plantar) injection
into the rat left hind paw of 100 μL of a λ-carrageenan solution (1% in
saline) as previously described [30]. Paw volume measurements were
as following: V0 or basal volume is the volume of the hind paw mea-
sured immediately after carrageenan injection and V6 is the volume at
6 h post carrageenan administration. The increase in paw volume was
measured as the oedema volume and was expressed as a relative per-
centage of the increase in the volume at 6 h compared to the initial
volume, according to the following formula: % paw volume increase =
[(V6-V0) / V0] x 100.
2.6.3. Experimental groups
Animals were randomly allocated into the following six groups: (i)
control group - animals were subjected to the oedema protocol de-
scribed above, with the exception of 100 μL of sterile saline being ad-
ministered via subplantar injection instead of carrageenan. Animals
were also administered with water (1 mL/kg) by oral gavage (n=6);
(ii) carrageenan group - animals with paw oedema induction as de-
scribed above and administered with 1mL/kg of water by oral gavage
(n=8); (iii)M. pulegium group - animals with paw oedema induction as
described above and administered with M. pulegium extract (15mg of
phenolic acids/kg by oral gavage) 30min before injection of carra-
geenan (n=8); (iv) indomethacin group - animals with paw oedema
induction as described above and administered with indomethacin
(10mg/kg by oral gavage) 30min before injection of carrageenan
(n=8); (v) tempol group - animals with paw oedema induction as
described above and administered with tempol (30mg/kg by oral ga-
vage) 30min before injection of carrageenan (n=8); (vi) trolox group -
animals with paw oedema induction as described above and adminis-
tered with trolox (10mg/kg by oral gavage) 30min before injection of
carrageenan (n=8). The dose of the extract was selected according to
previous studies by our group regarding the evaluation of the beneficial
effects of different phenolic extracts in several models of inflammation,
and the dose of 15mg/kg of phenolic acids has generated consistent
results and is also within the range of possibility for clinical translation
and use, considering a human adult of 70 kg [31–34].
2.7. TNBS-induced ulcerative colitis model in mice
2.7.1. Animals
Male mice (CD-1 strain), weighing 28–33 g (5–6 weeks of age)
(Harlan, Spain), were maintained according to the standard housing
guidelines with free access to water and food, in a room with en-
vironmental conditions automatically controlled (22 ± 1 °C with a 12/
12 h light/dark cycle) at the Animal Facility of the Faculty of Pharmacy
- University of Lisbon.
2.7.2. Induction of colitis
Induction of colitis was performed by administration of TNBS as
previously described [31]. Briefly, a 50% ethanolic solution of TNBS
(2.5% m/v) was administered by intracolonic administration (4 cm
above the anus). At day 4 post-induction, blood samples were collected
by cardiac puncture under surgical anaesthesia, followed by euthanasia
by cervical dislocation and subsequent necropsy. The colon was re-
moved and was observed for classification of diarrhoea severity.
Furthermore, the colon was washed with PBS for a macroscopic ob-
servation of lesions and fixed in PFA for histological studies.
2.7.3. Experimental groups
Mice were allocated in a randomized way into the following ex-
perimental groups:
1 Sham group (n=6): the colitis induction protocol was followed as
described above with the exception of the intracolonic administra-
tion being performed with 100 μL of saline solution instead of the
alcoholic TNBS solution. Animals were administered with 10mL/kg
of water by oral gavage throughout the four days of the experiment.
2 Ethanol group (n=6): the colitis induction protocol was followed
as described above with the exception of the intracolonic adminis-
tration being performed with 100 μL of 50% (v/v) ethanol solution
instead of the alcoholic TNBS solution. Animals were administered
with 10mL/kg of water by oral gavage throughout the four days of
the experiment.
3 TNBS group (n=10): the colitis induction protocol was followed as
described above, with the administration of 100 μL of a TNBS so-
lution (2.5% TNBS in 50% ethanol). Animals were administered
with 10mL/kg of water by oral gavage throughout the four days of
the experiment.
4 TNBS + M. pulegium group (n=10): the colitis induction protocol
was followed as described in the previous experimental group.
Animals were administered with M. pulegium extract (15mg/kg of
phenolic acids by oral gavage) throughout the four days of the ex-
periment.
2.7.4. Macroscopic evaluation of colitis severity
Diarrhoea severity was classified by an observer blinded to the ex-
perimental groups according to Table 1. A microscope observation of
the tissue was performed followed by measurement of the entire colon
and injury extent.
2.7.5. Histology and immunohistochemistry procedures
Haematoxylin & Eosin (H&E) staining was performed as previously
described [31], as well as the immunohistochemistry studies, for
measurement of COX-2 and iNOS expression. Briefly, the colons were
fixed in 4% PFA in PBS during 72 h at room temperature, decalcified,
dehydrated and embedded in paraffin. Immunostaining was done in
sections cut to a thickness of 6mm and application of the primary an-
tibodies, rabbit anti-COX-2 and rat anti-iNOS was performed, followed
by the secondary antibodies incubation: anti-rabbit and anti-mouse
antibodies for horseradish peroxidase (antibody catalogue numbers are:
COX2 – rabbit, Cell signalling #4842, d1:500; iNOS – mouse, BD
Biosciences #610329, d1:1000). Colon histological damage was scores
as follows: score 0 - normal colon with no lesions, the mucosa is of
uniform thickness, and the crypts are straight, normal crypt archi-
tecture, there is no cellular infiltration, oedema, or exudate; score 1 -
colon with mild lesions, there are mucosal erosion and small superficial
ulcers scattered along the length of the colon, with slight crypt loss and
mononuclear cell infiltration; score 2 - colon with moderate lesions,
intestines have extensive erosion and ulceration, with moderate crypt
loss and neutrophil infiltration; score 3 - colon with very severe ul-
ceration, much of the mucosa is thin with loss of crypts and markedly
Table 1
Score of diarrhoea severity.
Score Faeces consistency
0 Normal (hard pellets)
1 Slightly mucous
2 Soft
3 Liquid
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increased infiltration of neutrophils and acute inflammatory exudate.
The intensity of the protein staining is relatable to the level of expres-
sion of iNOS and COX-2. The level of iNOS or COX2 staining was
quantitatively evaluated by determining the percentage of tissue area
that was stained in brown, using the ImageJ (Fiji Is Just) software.
2.8. In vitro anti-proliferative cell assays evaluation
2.8.1. HT29 cell culture
The HT29 colon adenocarcinomas from Homo sapiens sapiens, cell
line ECACC, nº 91072201, was used in in vitro experiments, as pre-
viously described [31].
2.8.2. HT29 cell proliferation assay
HT29 cell proliferation assay was performed according to
Carmichael et al. [35] with modifications previously described [31].
2.8.3. Wound healing assay
The selected pennyroyal phenolic extract corresponding to an EC50
level of activity was assessed for its inhibitory activities in HT29 colon
adenocarcinoma cells using standard cell migration analysis (wound
healing assay) as previously described [31]. Data is presented as the
mean ± SD.
2.9. Evaluation of inhibition of matrix metalloproteinases (MMPs)
gelatinolytic activity
2.9.1. Minimal Inhibitory Concentrations (MICs) and half maximal
effective inhibition (IC50) inhibition
MMP-inhibition was tested using the DQ gelatin assay as described
in Lima et al. [36]. Minimal Inhibitory Concentrations (MICs) were
assessed using the micro dilution method as previously described [37].
2.9.2. MMP activity in HT29 colon cancer cells
MMP activity in HT29 cancer cells was performed by gelatin zy-
mography according to standard methods [38], with the modifications
previously described [31].
2.10. Animal in vivo experiments
Experiments were conducted according to the Home Office
Guidance in the Operation of Animals (Scientific Procedures) Act 1986,
published by Her Majesty's Stationary Office, London, UK, and the
Institutional Animal Research Committee Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health
(NIH Publication no. 85–23, revised 1996), as well as to the currently
adopted EC regulations (Directive 2010/63/EU). The studies were
performed in compliance with the ARRIVE Guidelines for Reporting
Animal Research summarized at http://www.
2.11. Statistical analysis
In the in vivo animal experiments the results were expressed as
mean ± standard error of the mean (SEM) of n observations (n re-
presenting the number of animals). Comparison of results was per-
formed by a one-factorial ANOVA test, followed by a Bonferroni's post
hoc test (Prism 6.0 software – GraphPad). Statically significances were
considered for P values less than 0.05.
In the in vitro and ex vivo studies with the HT-29 cells all experi-
ments were executed as triplicates (a 3 independent experiments) and
results were expressed as the mean ± standard deviation (SD).
Comparison of results was performed by the use of the software
SigmaPlot (12.5 version), with one-factorial ANOVA test followed by a
Tukey test for comparison between groups. Statistical differences were
considered significant when P < 0.05.
3. Results
3.1. Phenolic profile and antioxidant capacity of the M. pulegium phenolic
extract
Total phenolic and flavonoid content ofM. pulegium phenolic extract
is shown in Table 2. The chromatographic profile obtained for the
phenolic extract of M. pulegium is depicted in Fig. 1 and reveals that
there is a predominance of hydroxycinnamic acids (74.4%), followed by
hydroxymethoxyflavones (11.2%), catechins (9.6%) and hydro-
xybenzoic acids (4.8%).
The main component of the extract was identified as rosmarinic
acid, and accounts for 36.7% of the relative chromatographic area. The
main constituents of theM. pulegium phenolic extract are represented in
the graph depicted in Fig. 1.
In order to determine the antioxidant potential of M. pulegium ex-
tract reducing capacity (FRAP and CUPRAC) and free radical scaven-
ging activity (DPPH and O2− assay) assays were employed (Table 3).
The antioxidant capacity of M. pulegium extract was detected in all the
assays. Results obtained are in accordance with previous studies which
also demonstrated that ethanolic extracts of M. pulegium exhibit redu-
cing capacity and are able to scavenge reactive oxygen species
[13,39,40].
3.2. Paw oedema evaluation
Induction of oedema by carrageenan injection expectedly led to a
significant increase in the volume of the hind paw at 6 h post-carra-
geenan compared to the control group. Administration of M. pulegium
phenolic extract was able to reduce the oedema formation in a sig-
nificant way (Fig. 2). When comparing this effect to the ones exhibited
by administration of tempol (30mg/kg), trolox (30mg/kg) and in-
domethacin (10mg/kg), it became evident that M. pulegium phenolic
extract administration reduced oedema formation at only a slightly
lower magnitude as those known antioxidant and anti-inflammatory
substances (Fig. 2) at a dose of 12.5mg of phenolic acids/kg.
3.3. Macroscopical and functional signs of colitis injury
Animals from both the Sham Group and the Ethanol Group ex-
hibited no macroscopic evidence of colon lesion and mortality was of
0%. Rectal administration of TNBS/EtOH led to a statistically sig-
nificant: colon length decrease, length of injury formed (ulcer) increase
and diarrhoea severity increase, with a 30% mortality rate. In the
groups treated with the M. pulegium extract all macroscopic signs of
colon injury were significantly reduced comparing to the colitis-in-
duced animals (Table 4, Fig. 3). Macroscopical observations and pho-
tographs of the removed colon also confirmed these beneficial effects,
with a flaccid appearance and an abundance of liquid faeces. Ob-
servation of the colons through a surgical microscope was able to evi-
dently demonstrate that colon injury was attenuated in animals ad-
ministered with the extract when compared to the untreated colitis
animals (Fig. 3).
3.4. Histological features and inflammatory markers of colitis injury
The evaluation of histologic signs of injury (Fig. 4) showed that
Table 2
Total phenolic and flavonoid contents of M. pulegium extract.
Total phenolics Total flavonoids
mg GAE/mL mg GAE/ g dry plant mg CE/mL mg CE/g dry plant
1.09 ± 0.05 23.55 ± 1.12 2.79 ± 0.10 60.45 ± 2.15
All values are mean ± standard deviation of triplicates.
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healthy animals exhibited a colon with normal appearance, with no
evidence of lesions, a mucosa with a uniform thickness, crypts with
normal architecture and no observable signs of inflammatory events
(score 0). On the contrary, untreated colitis mice exhibited severe ul-
ceration with abnormal architecture crypts (with evidences of complete
loss) and a thinner mucosa with a clear evidence of immune cells in-
filtration, equivalent to a score of 3. Colons from animals administered
with M. pulegium extract show slight to moderate lesions with minimal
crypt alteration with less immune cell infiltration resulting in a damage
score of 1. As evidenced in Fig. 8, induction of colitis also led to a clear
increase of iNOS and COX-2 expression along the existing crypts (shown
in brown colour). In animals treated with M. pulegium extract the ex-
pression of both markers was significantly reduced with the iNOS ex-
pression being totally reduced in these animals, which further sup-
ported the histological observations (Fig. 5).
3.5. Cell invasion properties of HT-29 cells
Figs. 6 and 7, show that exposure to 200, 400 and 800 μg of phe-
nolics/mL of M. pulegium phenolic extracts reduced the proliferative
ability of HT-29 cells to invade their wounds, with a dose-dependent
effect. When using the EC50 concentration (regarding MMP inhibition)
the cell migration property assessed in the wound healing assay was
reduced by over 70% when compared to control.
Fig. 1. Main constituents and phenolic profile of the Mentha pulegium extract with identification of the functional groups from the main components: 1. HB -
hydroxybenzoic acid; 2-8. and 14-20. HC – hydroxicinnamic acids; 9-13. HMF – hydroxymetoxyflavones; 21,22. C - catequines.
Table 3
Antioxidant capacity of M. pulegium extract.
CUPRAC FRAP DPPH O2−. Assay
μmol AAE/mL μmol Fe2+/mL mg AAE/mL μmol GAE/mL
1.71 ± 0.07 10.29 ± 0.63 0.88 ± 0.02 9.23 ± 3.29
All values are mean ± standard deviation of triplicates.
Fig. 2. Effect of M. pulegium extract on the rat
paw edema development elicited by carra-
geenan 6 h after edema induction. Effect of a
single administration of M. pulegium extract
(12,5 mg of phenolic acids/kg, p.o.) in com-
parison with the effect of a single administra-
tion of indomethacin (10mg/kg, p.o., n= 8),
lycopene (50mg/kg, n= 8; p.o.), tempol
(30mg/kg, n=8; p.o.) and trolox (30mg/kg,
n= 8; p.o.) [1]. The data is presented as means
with their standard errors. *P < 0.01 vs Con-
trol Group; #P < 0.01 vs Carrageenan group;
θP < 0.001 vs Carrageenan group.
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3.6. Cell MMP activity in cultured HT-29 cells and colon tissue from the in
vivo colitis model
Gelatinolytic activity (Fig. 8a) showed that MMPs in HT-29 cells
were inhibited by the phenolic extracts from M. pulegium. Since the DQ-
gelatin assay provided evidence of total gelatinolytic activity in the
extracellular matrix, we further analysed the activity of MMP-2 and -9
through zymography (Fig. 8b). When observing the effects of the ex-
tract in MMP-2 expression, a visible inhibition was observed, sup-
porting the results evidenced in Figure 11a. Minimal inhibitory con-
centrations (MIC) for HT-29 cell growth and gelatinase activity was
quantified and are expressed in Table 5.
4. Discussion
Although the food industry has been mainly focused on the essential
oil of pennyroyal due to its known antibacterial properties and use as
food preservative, few studies have focused on phenolic extracts of
pennyroyal and, until now, no study has specifically investigated its
beneficial effects on IBD.
Zaidi et al isolated a series of hydroxylated metoxyflavones from
dried leaves of M. pulegium and M. suaveolens, using alcohol solvents
and purification by column chromatography [41]. Proestos et al. [42]
and Fatiha et al. [40] studied the crude ethanolic extracts obtained from
the dried leaves of M. pulegium and concluded that their main phenolic
components are hydroxybenzoic and hydroxycinnamic acids, flavones
and flavanones.
Taking into account the relative chromatographic areas of the main
components detected in the HPLC-DAD profile of the M. pulegium ex-
tract used in this work, it is evident that there is a predominance of
hydroxycinnamic acids (74.4%), followed by hydroxymethoxyflavones
(11.2%), catechins (9.6%) and hydroxybenzoic acids (4.8%) (Fig. 1).
The main component of the extract is rosmarinic acid, a hydro-
xycinnamic acid, and accounts for 36.7% of the relative chromato-
graphic area (Fig. 1).
This in line with other publications regarding the characterization
of the phenolic content of M. pulegium leaves extract. In 2018, Politeo
et al performed a phytochemical analysis as well as an evaluation of the
Table 4
Morphologic and functional observations of the colon, immediately after collection.
Length of colon (cm) Extent of injury Presence/Consistency of diarrhoea Mortality (%)
Sham 14.5 ± 0.08 0 0 0
EtOH 50% 14.1 ± 0.20 0 0 0
TNBS+EtOH 50% 11.8 ± 0.19# 3.6 ± 0.14# 3# 30
TNBS +
M. pulegium
14.3 ± 0.48* 3.5 ± 0.35# 1.75 ± 0.48* 25
# P < 0.05 vs Sham.
* P < 0.05 vs TNBS+EtOH 50%.
Fig. 3. Effect ofM. pulegium extract administration on the lenght of colon (cm), extent of intestine injury (cm) and visual macroscopic observation of the colon. Sham
group (n= 6), EtOH group (n=6), TNBS group (n= 10), TNBS + M. pulegium (n=10). #P < 0.001 vs Sham group, *P < 0.001 vs TNBS group.
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antioxidant and anticholinesterase potential of hot water and metha-
nolic extracts from M. pulegium L. [43]. Rosmarinic acid was the most
abundant compound in the tested extracts, followed by ellagic acid,
eriodictyol, naringenin and chlorogenic acid. The authors found that
the phenolic-rich extracts demonstrated good radical scavenging po-
tential, reducing power and ability to inhibit lipid oxidation. The tested
extracts also showed low ability to inhibit protein oxidation and low or
no acetylcholinesterase and butyrylcholinesterase inhibition potential.
In order to determine the antioxidant potential of M. pulegium ex-
tract, reducing capacity (FRAP and CUPRAC) and free radical scaven-
ging activity (DPPH and O2- assay) assays were employed (Table 3).
The antioxidant capacity of M. pulegium extract was detected in all the
screening assays (FRAP, CUPRAC, DPPH and superoxide assays) and
the results obtained are in accordance with previous studies which also
Fig. 4. Effect ofM. pulegium extract administration on the histological features of colon inflammation. Effect ofM. pulegium administration on the histological features
of colon inflammation. (A) Sham group (n= 6) shows a normal colon with no lesions and normal crypt architecture. (B) TNBS group (n=10) exhibits severe
ulceration with altered crypts and increased infiltration of immune cells (black arrow, score 2,5). (C) TNBS + M. pulegium group (n=10), exhibits colon with
mucosal erosion and small superficial ulcers scattered along the length of the colon, with slight crypt alteration and immune cell infiltration (black arrow, score 1).
Original magnification 100× . Scale bar equals 200 microns.
Fig. 5. Effect of M. pulegium extract administration on the colon tissue expression of COX-2 and iNOS. (A) – COX-2 expression; B) – iNOS expression. (1) Sham group
(n=6), (2) TNBS group (n= 10), (3) TNBS + M. pulegium group (n= 10). The samples from animals subjected to intestinal colitis showed marked expression of
COX-2 and iNOS (brown staining, arrows), while samples from M. pulegium extract treated animals exhibited marked reduction for both markers. Original mag-
nification x400. Scale bar equals 200 microns. Percentage of tissue area stained in brown, was obtained using the ImageJ (Fiji Is Just) software. *P < 0.05 vs Sham,
**P < 0.01 vs Sham, ##P < 0.01 vs TNBS.
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demonstrated that phenolic extracts of M. pulegium exhibit reducing
capacity and are able to scavenge reactive oxygen species [13,39,40].
Although, as previously mentioned, very few studies have focused
on the evaluation of biological activities of phenolic extracts of pen-
nyroyal (as well as other aromatic plants), the ones actually performed
and published appear to corroborate the results obtained in our study.
In a 2011 study by Moussaid and colleagues, five ethanolic extracts of
plants used in Moroccan traditional medicine were tested for their in
vitro antioxidant and in vivo anti-inflammatory activities (using a
carrageenan-induced ear oedema model in mice). The most active plant
in both properties was M. pulegium, which was also the plant that ex-
hibited a higher concentration of phenolics and flavonoids.
A study from Brahmi and colleagues [44] evaluated the antioxidant,
anti-inflammatory and cytoprotective effects of ethanolic extracts from
3 Mentha species from Algeria (M. spicata, M. pulegium and M. ro-
tundifolia) on murine RAW 264.7 LPS-treated macrophages. All the
extracts strongly reduced IL-6 secretion and two of them (M. pulegium
and M. rotundifolia) also decreased MCP-1 and TNF-α secretion. The
same authors previously characterized the phenolic content of the M.
pulegium extract, having identified as the main constituents rosmarinic
acid and diosmin [45].
Our results showed that the phenolic extract of M. pulegium (pen-
nyroyal) possesses a significant anti-inflammatory effect, identifiable in
an acute setting, as demonstrated by the reduction of paw oedema in
the carrageenan-induced oedema model. Furthermore, we were able to
demonstrate that administration of this extract to animals subjected to
colitis induction resulted in a significant reduction of several para-
meters that are mimicked in human IBD: intestinal inflammatory injury
(macroscopical and histological findings); diarrhoea severity and ex-
pression of inflammatory markers.
Previous studies by our group have shown that phenolic extracts
exhibited a beneficial effect in this model of IBD [31,34], where
Fig. 6. Effect of Pennyroyal extract administration on HT29 cell proliferation after exposure to 0, 50, 100, 200,400 and 800 μg total phenolics/mL of pennyroyal
extracts, quantified by the MTT method. Results are expressed as represent an average of at least three replicate experiments (n= 3)± SD. #P<0,001 vs Control.
Fig. 7. HT29 cell migration after exposure to phenolic extracts of pennyroyal as determined by wound healing assays. The histogram reports the relative migration
rates, where values are the means of at least three replicate experiments ± SD, and are expressed as % wound closure in relation to day 0. Cells were grown until
reaching 80% confluence and the monolayer was scratched with a pipette tip (day 0). Cells were then exposed to the phenolic concentrations equivalent of the
determined EC50 of MMP activity (500 g/mL). Cell migration was recorded after 48 h. ***P < 0.001.
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administration of persimmon and spearmint phenolic extracts at similar
doses also led to similar results. Although some of the more species-
specific compounds are not common to these plants, it proves the
concept that the same dose of total phenolic compounds has a beneficial
effect in the same experimental model of disease.
In the carrageenan-induced paw oedema model we observed a sig-
nificant reduction of oedema caused by local inflammation, in a mag-
nitude of effect that was comparable to substances used as positive
controls, a non-steroidal anti-inflammatory drug (indomethacin) and
two reactive oxygen species scavengers (trolox and tempol).
Although no direct correlation can me made regarding the me-
chanisms responsible for these effects, our results did show that not
only the pennyroyal extract possessed a high antioxidant capacity, but
the chemical profiling revealed a high concentration of rosmarinic acid,
a common aromatic herb constituent. Rosmarinic acid has also been
studied by our group and has revealed to be one of the main responsible
for the anti-inflammatory effect of a rosemary extract in local models of
acute inflammation in rodents and when administered isolated has
shown to reveal important anti-inflammatory effects in acute models of
critical care settings [30]. Recently, two studies have reported the effect
of administration of rosmarinic acid in another model of IBD, the DSS-
induced colitis in mice. In one of these studies, rosmarinic acid ad-
ministration (30mg/kg p.o. for 7 days after induction of colitis) sig-
nificantly reduced the severity of colitis and results suggested that the
suppression of colonic inflammation was related to a dual inhibition of
NF-κB and STAT3 pathways activation [46]. In our study we demon-
strated that two of the parameters that were reduced by administration
of rosmarinic acid were the protein expression of COX-2 and iNOS.
Studies have been shown that diet polyphenols were able to inhibit
several transcription factors known to induce COX-2 and iNOS ex-
pression (NF-κB, JAK/STAT and MAPK), in general processes of in-
flammation and immunomodulation [10], intestinal inflammation [47]
and CRC [48]. In a second study, administration of rosmarinic acid (25,
Fig. 8. Effect of pennyroyal extract on the gelatinase activity of MMP-2 and MMP-9.
a) Effect of pennyroyal extract after exposure of isolated MMPs to 0, 50, 100, 200,400 and 800 μg total phenolics/mL of ppennyroyal extracts, as quantified by the DQ
fluorogenic method. Results are expressed as relative fluorescence as a % of controls and represent an average of at least three replicate experiments (n= 3)± SD.
b) Effect of Pennyroyal extract administration on the gelatinase activity of MMP-2 and MMP-9 in HT-29 cells.
b1 - Proteolytic activity of gelatinases present in the HT29 extracellular media after a 48 h exposure to 0 and 500 μg total phenolics.mL-1 of pennyroyal extracts, as
quantified by the DQ fluorogenic method. Results are expressed as relative fluorescence as a % of controls and represent an average of at least three replicate
experiments (n=3)± SD. ⁎P < 0.05.
b2 - Representative image of the zymographic profiles of MMP-9 and MMP-2 activities in HT29 extracellular media after a 48 h-exposure to 0 and 500 μg/mL). HT29
extracellular media was loaded in 12.5% (w/v acrylamide) polyacrylamide gels co-polymerized with 1% (w/v) gelatin. C= controls and P=pennyroyal extract. *
*P < 0.001.
Table 5
Minimal inhibitory concentrations against HT29 cell growth and gelatinase
activity. Values are in μg total phenolics.mL-1.
MIC (μg total phenolics/mL)
HT29 cell growth 5.2
HT29 Gelatinase activity 2670
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50 and 100mg/kg p.o. 3 days before colitis induction and then daily for
8 days) significantly decreased disease severity and histological score of
colons in DSS-induced colitis mice [49]. Particularly for the higher
dose, rosmarinic acid administration was able to reduce nitric oxide
(NO) production and, among other inflammatory mediators, also re-
duced the expression of iNOS and COX-2. Inhibition of NO production
can be directly correlated to reduction of iNOS expression and is an
important target in inflammatory processes since NO is an important
initiator of oxidant and proinflammatory pathways. Its role in human
IBD has also been investigated and studies have shown that the level of
NO production by iNOS exhibits a high correlation with the intensity of
disease in IBD [50] and was in fact proposed as a new and useful bio-
marker in the clinical setting, namely in diagnostic protocols and in the
monitoring of patients with colitis or Crohn's disease [51]. Pro-in-
flammatory cytokines at the site of inflammation can induce COX-2
expression and increase the synthesis of prostaglandins that conse-
quently are able to stimulate cancer cell proliferation, promote angio-
genesis, inhibit apoptosis, and increase metastatic potential [48]. The
influence of increased COX-2 expression and upstream pathways that
regulates it have been shown to be of significant relevance in IBD and
CRC in humans [52,53].
Our results show that administration of a pennyroyal extract at a
dose of 15mg/kg (of phenolic acids) was able not only to reduce the
severity of colitis but also to reduce the expression of COX-2 and iNOS
(among other parameters) with just 4 days of treatment.
Another inflammatory mediator that might also contribute to the
beneficial effect of pennyroyal administration in this animal model of
colitis, is the expression of matrix metalloproteinases (MMP). Matrix
metalloproteinases (MMPs) are considered to be relevant proteases in-
volved in the pathogenesis of IBD through their ability to remodel the
extracellular matrix in response to inflammatory stimuli and by their
immunomodulating effects [54]. Also, genetic studies performed in
humans show that genetic variations in MMPs may be associated with
increased risk of ulcerative colitis and may play a role in interindividual
differences in UC susceptibility and clinical outcome [55]. Additionally,
MMPs are enzymes that play a crucial role in the transformation and
progression of tumours, especially during the invasion and metastasis
stages [56] and some preclinical and even clinical studies have already
shown that MMP-2 and MMP-9 expression and activation might be of
great relevance for migration and invasion of CRC cells, leading to fa-
cilitation of angiogenesis and metastasis [57,58]. Here we evaluated the
inhibitory effect of the pennyroyal phenolic extract in the gelatinolytic
activity of both MMP-2 and MMP-9 in HT29 CRC cells. Our results
showed that pennyroyal extract was able to reduce the activity of both
MMP-2 and MMP-9. Furthermore, we were able to observe a significant
inhibitory effect of both the proliferation and invasibility properties of
HT-29 CRC cells.
Given the relevance of MMP activity in inflammatory and onco-
genesis processes, studies have been performed to investigate the
multiple pathways upstream MMP expression that are able to regulate
it. Not surprisingly, some of the most influent pathways involved in the
increased expression of MMPs are also crucial pathways and tran-
scription factors closely related to inflammatory pathways responsible
for intestinal inflammation and progression to colorectal cancer, such as
the above mentioned NF-κB, STAT and MAPK pathways [59,60], AP-1
and PKC [60,61].
As mentioned in the introduction section, a well-established con-
nection exists between IBD and CRC. Dyson and colleagues have ex-
tensively characterized the risk factors involved in this connection,
having identified the following risk factors has being the most relevant:
the duration and extent of colitis, the severity of inflammation and the
existence of family history of sporadic colorectal cancer [62]. Kraus and
colleagues have pointed out the cumulative effect of chronic in-
flammation and its correlation with inflammation severity and disease
extent and duration as the main link between IBD and the elevated CRC
risk [63]. Although the exact mechanisms and pathways are not yet
elucidated, mainly due to a pleiotropic effect and cross-link between
several inflammatory pathways, chronic inflammation is considered to
be the main driver towards initiation and promotion of cancerous
processes in the colon. Increasing evidence points to two key genes in
the inflammatory process, cyclooxygenase-2 (COX-2) and nuclear factor
kappaB (NF-kB), that may provide a mechanistic link between in-
flammation and cancer while other factors such as, TNF-a and IL-6-
induced signaling have been recently shown to promote tumor growth
in experimental models of colitis-associated cancer [63]. Therefore,
colitis-associated cancer appears to be influenced by inflammatory
processes, an imbalance in intestinal microbiota, and a crosstalk be-
tween various signaling pathways. A clear mechanistic origin is not yet
identified but a link through a molecular crosstalk of multiple in-
flammatory loops including TGFβ, NFKB, TNFα and ROS are a few
possibilities [64].
In conclusion, our results show, to our knowledge for the first time,
a beneficial effect of M. pulegium (pennyroyal) phenolic extract on the
amelioration of IBD severity and on the impairment of processes re-
levant for progression into CRC. Given the role of inflammatory pro-
cesses in the progression of colorectal cancer and the important link
between inflammation and cancer, these results might open new re-
search opportunities for the adjuvant therapeutic management of IBD
patients.
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